Supravalvular aortic stenosis (SVAS) is
Introduction
Elasticity of the skin, lungs and large blood vessels depends on the presence of elastic fibres in the extracellular matrix. Abnormalities of elastic fibres, which are composed mainly of amorphous elastic (95%) and microfibrils, cause several cardiovascular, connective tissue and skin disorders, including Marfan syndrome, supravalvular aortic stenosis (SVAS) and Cutis Laxa. [1] [2] [3] [4] SVAS is an obstructive vascular lesion with an incidence of 1/20 000 births, described in 1842 by Chevers, 5 and was the first disorder to be associated with the elastin gene (ELN). The aortic narrowing can occur as a discrete hourglass deformity or as diffuse aortic hypoplasia and may be associated with other vascular lesions, the association with pulmonary arterial stenoses being well recognised. SVAS can occur sporadically or as an autosomal dominant condition with reduced penetrance. 6 The severity of SVAS is variable but it may be progressive, leading to cardiac failure and early death without surgical intervention. A chromosomal translocation t(6;7)(p21.1;q11.23) that segregated with SVAS in a family first suggested that mutations in the ELN gene located at 7q11.23 might be a cause of SVAS. 7 Subsequently, gross deletions of ELN were identified in two cases of SVAS. 8, 9 We, and others, have since described point mutations in the ELN gene in both familial and sporadic cases of SVAS. 10, 11 SVAS also occurs as one component of Williams-Beuren syndrome (WBS), 12 a complex developmental disorder caused by a deletion of about 1.4 Mb of chromosome 7q11. 23 , which takes out a number of contiguous genes, including ELN. 13 Comparing WBS patients and patients with isolated SVAS, it appears that hemizygosity for elastin causes SVAS and, sometimes, peripheral artery stenosis, and hernias, but not the other features of WBS. 14 In an attempt to define the molecular pathology of SVAS, we have screened 100 patients, ascertained from a range of sources in the UK and abroad, with either familial or sporadic supravalvular stenosis and/or other vascular abnormalities, for mutations in all 34 exons of the ELN gene. The relationship between the type of mutation found and the penetrance of SVAS within families as well as other possible genotype/ phenotype correlations were investigated. In this way we can attempt to identify the pathogenic mechanisms involved in this cardiovascular disorder.
Materials and methods

Clinical ascertainment of patients
The samples were referred in from various centres. Patients were ascertained based on cardiological diagnosis of SVAS on echocardiogram, ( + /-) angiography. SVAS patients were classified as severe (s) if they had surgical procedures, moderate (m) if they were still under follow-up by clinicians and mild, if stated as mild and often under no further followup.
Elastin FISH and microsatellite analysis
Elastin FISH was carried out using the Oncor WSCR probe according to the manufacturer's instructions (Appligene Oncor Lifescreen, Hertfordshire, UK). Haplotype analysis of patients was carried out by PCR amplification of genomic DNA using the following markers: All amplifications were carried out using 100 ng of genomic DNA and 10 pmol of each primer in 20 µl reaction volumes. Cycle conditions were: 95°C for 2 min, then 27 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1 min, with a final extension step of 5 min at 72°C. PCR products were electrophoresed on 8% polyacrylamide gels (acrylamide:N,N' bisacrylamide 19:1) for 3 h at 300 V then visualised by silver staining.
Mutation detection and sequencing ELN exons were amplified using primers and amplification conditions described previously. 10 In addition exon 18 was amplified using the following primers to avoid the microsatellite repeat: ELN: X18F: ATA CTC TAC TAA CCA CCC TTC TA ELN: X8R: ACA CAC ACA CAC AGC CCA GCT C Mutations were detected by a comparison of SSCP and heteroduplex analysis, products run on 1 mm non-denaturing 8% polyacrylamide gels and visualised by silver staining as previously described. 10 Mutations were initially characterised by fluorescent cycle sequencing (Thermo Sequenase II, Amersham, Bucks, UK) of column purified PCR products in both orientations with a matched control on an ABI 373 sequencer.
Mutation screening of pedigrees
Screening for the exon 17 mutation in family no. 91 MluI digested PCR products were separated on a 2% agarose gel and visualised by ethidium bromide staining.
Screening for the exon 6 mutation in family no. 106 BstNI digested PCR products were separated on a 2% agarose gel and visualised by ethidium bromide staining.
Cloning exon 26 alleles in patient no. 11
Exon 26 PCR amplified products from patient no. 11 were cloned using the TOPO TA cloning kit (In Vitrogen, The Netherlands) according to the manufacturer's instructions. Plasmid minipreps were made from 10 clones, using the Qiagen miniprep kits, and sequenced in both orientations using the M13 reverse and forward vector primers (fluorescent cycle sequencing, Amersham). The mutations were confirmed in at least four different clones to insure that false base changes due to Taq polymerase proofreading errors were accounted for.
ARMS PCR of S442G polymorphism ARMS PCR was carried out using primers designed to amplify the mutant allele only: 
Results
Mutations in the ELN gene
One hundred unrelated patients with SVAS and vascular abnormalities were screened for mutations in the elastin gene, using a combination of SSCP and heteroduplex analysis. All these patients gave a positive FISH signal with elastin probes, showing that they did not have major deletions of the ELN gene (data not shown). Mutations were identified in 35 of the patients. These are described in Table 1 . Additionally five common polymorphisms were identified. Other previously published SVAS mutations are also listed in Table 1 to provide a comprehensive list of mutations published to date.
Premature termination mutations
Twenty-three nonsense or frameshift mutations were detected and, if translated, would result in truncated proteins lacking the C-terminal region of elastin. The C-terminus encodes important functional domains that includes for example: exon 30 (the site of a 10 bp element thought to control mRNA decay), and exon 34 (encodes residues required for interaction with the MAGP protein during elastogenesis (see Figure 1 ).
Splice site mutations
Base substitutions at the GT/AG consensus splice sites were seen in four patients: no. 66 (intron 14 acceptor, AG > AC), no. 68 (intron 7 acceptor, AG > CG), no. 69 (intron 3 donor, GT > TT) and no. 91 (intron 16 acceptor, AG > CG). Two families (nos 116, 630) had the same insertion of a single C base, 11 bases downstream from the start of intron 23. This variant was not seen in 200 controls and further elastin mRNA analysis would be required to see if it affects splicing. In all cases the exons flanking the altered splice site are frame-neutral, so that aberrant splicing would not be expected to disrupt the reading frame.
Changes affecting initiation of translation
Two families (nos 112 and 661) had small deletions in exon 1 encompassing the ATG initiation codon. These deletions should not prevent transcription, but lack of translation would lead to a null allele and haploinsufficiency for elastin. In patient no. 070 a novel upstream ATG codon is created at position -35 nucleotides (ACG > ATG). However, the lack of a Kozak consensus sequence 15 surrounding this site suggests it is unlikely to be functional. This patient had an additional clearly pathogenic nonsense mutation, Y150X. Parental samples were not available to check whether the two changes were in cis or trans.
Missense mutations
Four patients had missense mutations not present in 200 controls. In family no. 15 the exon 13 mutation P220L was present in the proband and his affected mother. A sporadic case (patient no. 500) had A707D in exon 30. Another sporadic case (patient no. 11) had a dinucleotide substitution in exon 26, GG > CA, resulting in the aminoacid substitution G610Q. Sequencing of cloned PCR products showed that the two changes were in cis. One of the two substitutions, 1828G > C, encoding G610R, is a common polymorphism (discussed below) and was present in the patient's father, but the second change occurred de novo. Finally, patient no. 102 has an apparent missense mutation, A55T, which replaces the last nucleotide of exon 3 (G) with (A). Such substitutions are known to affect the adjacent splice site because of their proximity to the consensus splice junction (GT).
Recurrent mutations
The Y150X (exon 9) and Q442X (exon 21) mutations were each seen in four apparently unrelated patients. K176X and the arguably pathogenic intron change, 1501 + 11 ∧ 12insC were each seen in two patients. Haplotype analysis of the patients using flanking and intragenic markers (D7S2476, ELN Helg18/19, LIMK1, D7S613) showed no evidence of founder effects for these mutations (data not shown). Elastin: mutational spectrum in SVAS K Metcalfe et al y
Intragenic polymorphisms
Intrafamilial variability
Clinical details collected on two large families (no. 91 and no. 106) with multiple affected members and defined mutations illustrate the phenotypic variability within families. Faster mutation-specific digestion tests were set up for screening other family members. Family no. 91 had 13 carriers of a splice site mutation. Five were asymptomatic, whilst other mutation carriers had symptoms ranging from mild to severe SVAS requiring surgery (Figure 2) . In family no. 106, mutation testing could only be performed on the proband III-4 and her sister III-7. In addition there are three sudden infant deaths, one an infant with proven SVAS and two with cardiovascular problems; two surviving children with SVAS or pulmonary stenosis, and three other possibly affected adults (Figure 3) . No ELN mutations were found in 64 patients with SVAS included in the study. These were clinically typical SVAS patients but the majority were sporadic. Eight cases were reported as familial but linkage support for the role of elastin was not carried out due to the small number of family members available for analysis. The SSCP/HD technique employed in this study has a 90% detection rate, so we cannot exclude the presence of point mutations in these patients. The presence of whole exon deletions within the ELN gene (not seen by FISH analysis), is also possible, and skin fibroblasts are being obtained from these patients for further screening. Alternatively, mutations in another gene could also cause SVAS.
Discussion
We have identified 35 patients with point mutations in the elastin gene many of whom have other vascular abnormalities. There appear to be mutation hotspots in exons 9 (Y150X) and 21 (Q442X -also reported in a sporadic case by Li et al 15 ) of the ELN gene. Mutation K176X was detected in two of our families, and mutation R570X was also described in a sporadic SVAS case by Li et al. 11 None of these families are known to be related and we found no evidence for a founder effect in our cases. Marked intra and interfamilial variation in phenotype is seen and there does not appear to be any good genotype-phenotype correlation, ie cases with missense mutation or splicing were just as likely to have severe SVAS as cases with truncating mutations. Disease severity within our SVAS families has varied from asymptomatic carriers of the mutation, to individuals dying in infancy from severe cardiac disease. Long term follow-up of aortic and pulmonary vascular lesions in WBS patients with SVAS has shown that individuals with moderate pressure gradients (exceeding 20 mm Hg) can present with pressure increases later in life, often requiring surgical intervention for the life-threatening vascular narrowing. 17, 18 Isolated SVAS may also be progressive and such patients require follow-up but the situation with regard to monitoring of mutation carriers with no apparent cardiovascular abnormalities is not resolved.
Two mechanisms for the pathology of SVAS can be proposed: the defects in elastin could be quantitative (haploinsufficiency for elastin) or qualitative (aberrant tropoelastin resulting in abnormal elastic fibres).
The hypothesis of a quantitative defect appears the most attractive because hemizygosity for elastin is already established as the mechanism for SVAS in patients with partial deletions involving ELN and in WBS. 13 All classic WBS patients described are hemizygous for the elastin gene, but there is considerable variability in the severity of vascular lesions seen. Variable penetrance is typical of diseases associated with haploinsufficiency, where genetic background is expected to have a major modifying effect on development of the phenotype.
Functional hemizygosity also appears to be the mechanism by which the majority of the SVAS point mutations exert their effect. Mutations affecting the ELN translation start site are essentially null alleles (6%), and the truncating mutations (66%) probably result in haploinsufficiency for elastin through nonsense mediated mRNA decay. 19 It is not, however, clear if splicing and missense mutations would result in a simple loss of function. These mutations could result in exon skipping, or frameshifts through activation of cryptic splice sites. Indeed, Urban et al 20 have described a SVAS patient with an acceptor splice site mutation that causes both exon skipping and activation of a cryptic splice, leading to a frameshift. Because the elastin gene has many small in-frame exons, exon skipping should be well tolerated, especially since elastin undergoes naturally occurring alternative splicing in vivo. It is worth noting that all the splicing mutations we detected at the consensus splice junctions are predicted to induce skipping of exons not normally spliced out. This suggests that they are important for the structural integrity of the elastic matrix and their exclusion is likely to be pathogenic. If abnormal tropoelastin proteins are synthesised they could interfere with elastic fibre assembly in a dominant negative manner, resulting in aberrant fibre formation during vasculogenesis and SVAS. The role of the missense mutations in the pathology of SVAS is more intriguing. Three occur in exons reported to be spliced out in vivo (exons 13, 26 and 30). 20, 21 Alternative splicing-out of a proportion of these mutated exons should result in some degree of phenotypic rescue; however, all three patients had severe SVAS. One explanation could be that the missense mutations activate cryptic splice sites that induce additional splicing out of that exon. This could upset the overall balance of tropoelastin isoforms present at certain developmental stages, which may be important for tissuespecific elastic fibre assembly. In fact, a specific element within exon 30 of tropoelastin mRNA has been shown to be involved in posttranscriptional regulation of elastin production in mature tissue, 22 and increased splicing out of this exon may have pathogenic consequences on tropoelastin expression during development. The physiological consequences of haploinsufficiency for elastin can be followed in studies on hemizygous mouse knockouts (ELN -/ + ). 23 Both humans and mice respond to ELN hemizygosity during development, by increasing the number of elastic lamellar units in their aorta, thereby increasing the risk of obstructive vascular disease. Whether aberrant tropoelastin and the formation of abnormal elastic fibres would also lead to SVAS via the same physiological mechanism remains to be determined, but we expect that would be the case. Future work will concentrate on providing evidence for the existence of a dominant negative mechanism for the pathology of SVAS. 
